-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Anti-VEGF drug is a monospecific antibody, which is characterized in that it can effectively inhibit the formation of new blood vessels and promote the regression of existing new blood vesse.
It plays an important role in diabetic retinopathy, retinal vein thrombosis and other diseas.
In the context of increasing aging, anti-VEGF drugs have a large and growing patient populati.
From the perspective of the domestic anti-VEGF drug market structure, Kanghong Pharmaceutical's Conbercept, Roche/Novartis' ranibizumab, and Regeneron/Bayer's aflibercept make up three market segmen.
However, in recent years, in the face of the considerable ophthalmic drug market, many domestic and foreign pharmaceutical companies have actively entered the market, and the anti-VEGF innovative drugs and innovative dual antibodies have accelerat.
on the w.
Not long ago, Qilu Pharmaceutical announced that the application for marketing authorization of aflibercept intraocular injection solution submitted by the company in April this year was accepted by the Drug Evaluation Center of the State Food and Drug Administrati.
First imitation list.
In addition to Qilu Pharmaceutical, there are also Boan Bio's aflibercept intraocular injection in the third clinical stage, and Clover Bio's aflibercept intraocular injection in the application clinical sta.
Bio-Tech recently stated on the interactive platform that the clinical trial of the company's ophthalmic drug BAT5906 is progressing as plann.
The phase II clinical trial for wAMD has completed the enrollment of all patients in September 2021, and is currently under normal follow-up; the phase III clinical trial for wAMD is undergoing ethics, contract negotiation and other processes in each center; for DME Ib/IIa clinical trials Part of the patient enrollment has been completed, and it is currently in progress as plann.
It is planned to complete the enrollment of all patients in the near future, and the phase III study for DME indications will also begin preparatio.
Sunshine Guojian announced in June 2021 that the recombinant anti-VEGF humanized monoclonal antibody independently developed by the company is currently undergoing “an evaluation of 601A (ophthalmology) in choroidal neovascularization (pmCNV) secondary to pathological myop.
A multicenter, randomized, double-blind, active drug-controlled phase II clinical trial of safety and efficacy in patients with visual impairment caused by .
The project has successfully completed the enrollment of the first subje.
For another example, Innovent's IBI302 is an anti-VEGF and anti-complement dual-target-specific recombinant fully human fusion protein, which is currently in clinical phase II, with the same indications for wAMD and D.
It is reported that this product is an innovative drug independently developed by Innovent for the treatment of ocular fundus diseas.
It is a First-in-Class anti-VEGF-anti-complement dual target molecule, and has been approved as a Class 1 new drug by the Ministry of Science and Technology of the People's Republic of Chi.
suppo.
In the following research, the company has stated that in addition to focusing on the improvement of vision and retinal thickness, it will also explore the efficacy of IBI302 in intractable diseases such as retinal fibrosis and macular atrophy, which is expected to further benefit the majority of patients with fundus diseases and their famili.
The industry believes that Qilu's aflibercept-like drugs may mean the beginning of the future VEGF drug research and development ti.
It is estimated that in the next three to five years, VEGF-targeted Leizhu, aflibercept-like drugs and innovative drugs around VEGF targets will be develop.
will be listed in successi.
In the face of the current increasingly fierce market competition for ophthalmic VEGF in China, some pharmaceutical companies are also actively responding, such as by promoting the launch of new indications, accelerating the inclusion of medical insurance, and exploring the road to internationalizati.
In general, a new competitive change is comi.
Click to enter the exhibition page
It plays an important role in diabetic retinopathy, retinal vein thrombosis and other diseas.
In the context of increasing aging, anti-VEGF drugs have a large and growing patient populati.
From the perspective of the domestic anti-VEGF drug market structure, Kanghong Pharmaceutical's Conbercept, Roche/Novartis' ranibizumab, and Regeneron/Bayer's aflibercept make up three market segmen.
However, in recent years, in the face of the considerable ophthalmic drug market, many domestic and foreign pharmaceutical companies have actively entered the market, and the anti-VEGF innovative drugs and innovative dual antibodies have accelerat.
on the w.
Not long ago, Qilu Pharmaceutical announced that the application for marketing authorization of aflibercept intraocular injection solution submitted by the company in April this year was accepted by the Drug Evaluation Center of the State Food and Drug Administrati.
First imitation list.
In addition to Qilu Pharmaceutical, there are also Boan Bio's aflibercept intraocular injection in the third clinical stage, and Clover Bio's aflibercept intraocular injection in the application clinical sta.
Bio-Tech recently stated on the interactive platform that the clinical trial of the company's ophthalmic drug BAT5906 is progressing as plann.
The phase II clinical trial for wAMD has completed the enrollment of all patients in September 2021, and is currently under normal follow-up; the phase III clinical trial for wAMD is undergoing ethics, contract negotiation and other processes in each center; for DME Ib/IIa clinical trials Part of the patient enrollment has been completed, and it is currently in progress as plann.
It is planned to complete the enrollment of all patients in the near future, and the phase III study for DME indications will also begin preparatio.
Sunshine Guojian announced in June 2021 that the recombinant anti-VEGF humanized monoclonal antibody independently developed by the company is currently undergoing “an evaluation of 601A (ophthalmology) in choroidal neovascularization (pmCNV) secondary to pathological myop.
A multicenter, randomized, double-blind, active drug-controlled phase II clinical trial of safety and efficacy in patients with visual impairment caused by .
The project has successfully completed the enrollment of the first subje.
For another example, Innovent's IBI302 is an anti-VEGF and anti-complement dual-target-specific recombinant fully human fusion protein, which is currently in clinical phase II, with the same indications for wAMD and D.
It is reported that this product is an innovative drug independently developed by Innovent for the treatment of ocular fundus diseas.
It is a First-in-Class anti-VEGF-anti-complement dual target molecule, and has been approved as a Class 1 new drug by the Ministry of Science and Technology of the People's Republic of Chi.
suppo.
In the following research, the company has stated that in addition to focusing on the improvement of vision and retinal thickness, it will also explore the efficacy of IBI302 in intractable diseases such as retinal fibrosis and macular atrophy, which is expected to further benefit the majority of patients with fundus diseases and their famili.
The industry believes that Qilu's aflibercept-like drugs may mean the beginning of the future VEGF drug research and development ti.
It is estimated that in the next three to five years, VEGF-targeted Leizhu, aflibercept-like drugs and innovative drugs around VEGF targets will be develop.
will be listed in successi.
In the face of the current increasingly fierce market competition for ophthalmic VEGF in China, some pharmaceutical companies are also actively responding, such as by promoting the launch of new indications, accelerating the inclusion of medical insurance, and exploring the road to internationalizati.
In general, a new competitive change is comi.
Click to enter the exhibition page
